Comparison of dexmedetomidine, pethidine and tramadol in the treatment of post-neuraxial anaesthesia shivering by Fern, L & Misiran, K
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/ojaa 21
South Afr J Anaesth Analg
ISSN 2220-1181           EISSN 2220-1173 
© 2015  The Author(s)
RESEARch
Southern African Journal of Anaesthesia and Analgesia 2015; 21(1):21-26
http://dx.doi.org/10.1080/22201181.2015.1013323
Open Access article distributed under the terms of the 
Creative Commons License [CC BY-NC-ND 4.0] 
http://creativecommons.org/licenses/by-nc-nd/4.0
Southern African Journal of Anaesthesia and Analgesia is co-published by Medpharm Publications, NISC (Pty) Ltd and Cogent, Taylor & Francis Group
South Afr J Anaesth Analg
IS N 2 0-1 81 EISSN 2220-11
© 2015 The Author(s)
CH
thern African Journal of Anaesthesia nd Analgesia  2015; 1(1):1–6
tp: /dx.d i.org/ .1080/22201181.2015.1013323 
en A cess article distrib ted under the terms of the
r ative Co mons License [CC BY-NC-ND 4.0]
http://creativecommons.org/licenses/by-nc-nd/4.0
Comparison of dexmedetomidine, pethidine and tramadol in the treatment of 
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Objective: This study was performed to compare the effectiveness of intravenous dexmedetomidine with that of pethidine and 
tramadol in the treatment of post-neuraxial anaesthesia shivering.
Design: This was a prospective, randomised, double-blinded study.
Setting and subjects: One hundred and two patients of both genders, aged 18–70 years with American Society of Anesthesiologists 
physical status I and II undergoing spinal or combined spinal and epidural anaesthesia for elective surgery were enrolled in this 
study. Sixty of them developed shivering after an intrathecal injection of 0.5% hyperbaric bupivacaine 15 mg. They were then 
randomly allocated to receive either intravenous dexmedetomidine 0.5 μg/kg, pethidine 0.5 mg/kg or tramadol 0.5 mg/kg.
Outcome measures: The response rate to treatment, the degree of sedation and the side-effects were recorded.
Results: The response rate to treatment was highest in the dexmedetomidine group, and it was only significant when compared 
to tramadol group (p = 0.0012). It was noted that the response rate was higher in the pethidine than in the tramadol group. This 
difference was not statistically significant (p = 0.082). The sedation score post treatment was similar in all three groups, but more 
patients in the dexmedetomidine group developed hypotension and bradycardia (p < 0.05).
Conclusion: Dexmedetomidine 0.5  μg/ml was more effective than tramadol 0.5  mg/ml and pethidine 0.5  mg/ml, and both 
tramadol and pethidine were found to have similar efficacy, in the treatment of post-neuraxial anaesthesia shivering. However, 
dexmedetomidine caused a higher incidence of hypotension and bradycardia.
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Introduction
Shivering may be defined as an involuntary, repetitive activity in 
the skeletal muscle. Shivering usually occurs as a thermoregulatory 
response to cold, although non-thermoregulatory shivering may 
also occur. The core temperature in humans varies with the 
circadian rhythm (and with the menstrual cycle in females), but is 
normally maintained within the narrow range of 36.5–37.0 °C.1
Shivering is a relative common problem encountered after 
neuraxial (spinal and epidural) anaesthesia. An incidence of 
shivering of up to 55% has been reported.1 Neuraxial 
anaesthesia produces vasodilatation, which facilitates rapid 
heat loss and the core to peripheral redistribution of body heat, 
causing the core temperature to decrease. Therefore, the 
shivering threshold is reached sooner, and more shivering is 
required to prevent further hypothermia.2 According to the 
study conducted by Kurz et al., neuraxial anaesthesia, either 
spinal or epidural anaesthesia, impaired the centrally mediated 
thermoregulatory responses. The mechanism remains 
unknown, but is most likely to result from altered afferent 
thermal input from the blocked region.3 Although shivering 
is not a life-threatening process, it can be a source of 
patient discomfort, and may interfere with the monitoring of 
the electrocardiogram, blood pressure and pulse oxygen 
saturation.4 It can also have deleterious metabolic and 
cardiovascular effects, which include increased expenditure of 
cardiac and systemic energy, increased oxygen consumption by 
approximately 100%, increased carbon dioxide production and 
increased cardiac work.5,6 Therefore, shivering should ideally be 
prevented or treated by pharmacological or other means.
Tramadol hydrochloride, a centrally acting analgesic drug, is 
effective in the treatment of post-anaesthetic shivering after 
general and neuraxial anaesthesia.2 It inhibits the neuronal 
reuptake of noradrenaline and 5-hydroxytryptamine (5-HT), 
facilitates 5-HT release and activates the μ-opioid receptors. Each 
of these actions is likely to influence thermoregulatory control.4 
The study by De Witte et al. showed that tramadol reduced the 
sweating, vasoconstriction and shivering threshold.7 In the study 
by Chan et al., intravenous tramadol effectively controlled 
shivering during Caesarean delivery under neuraxial anaesthesia 
with minimal side-effects.8
Pethidine, an opioid derivative, is frequently recommended for 
the treatment of post-neuraxial anaesthesia shivering.4 Pethidine 
is a combined μ- and κ-receptor agonist. Although its mechanism 
of anti-shivering effect has yet to be fully elucidated, it was 
indicated in a study in which naloxone was used that pethidine 
may act via the κ-, rather than μ-opioid, receptors. The anti-
shivering action of pethidine was inhibited by high-dose 
naloxone, which blocked the μ- and κ-receptors, but not by low-
dose naloxone which only blocked the μ-receptors.9 Activation 
of the κ-opioid receptors decreased the shivering threshold 
twice as much as the vasoconstriction threshold.10 However, 
pethidine probably acts directly on the thermoregulatory centre, 
and not only through receptor activation.4
Dexmedetomidine, a potent alpha 2-adrenergic receptor agonist, 
has been used as a sedative agent and is known to reduce the 
shivering threshold. It acts by decreasing the vasoconstriction 
and shivering thresholds. Bicer et al. showed that one dose of 
prophylactic administration of intraoperative dexmedetomidine 
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(1.0 μg/kg) before the end of the surgery reduced vasoconstriction, 
as well as shivering threshold.11 A study performed by Easley et al. 
showed that dexmedetomidine (0.5  μg/kg) was effective in 
treating post-anaesthetic shivering in children.12
Objective
The purpose of this study was to compare the efficacy of 
intravenous dexmedetomidine 0.5 μg/kg with that of pethidine 
0.5 mg/kg and tramadol 0.5 mg/kg in the treatment of shivering 
in patients undergoing elective surgery under neuraxial 
anaesthesia in Universiti Kebangsaan Malaysia Medical Centre 
(UKMMC), Kuala Lumpur.
Method
This was a prospective, double-blinded and block randomisation 
study conducted in the UKMMC, Kuala Lumpur, following 
approval from the Dissertation Committee of the Department of 
Anaesthesiology and Intensive Care, UKMMC, and the Research 
and Ethics Committee of the UKMMC (Research No. FF-231-2011).
Following patient informed consent, 102 patients of both 
genders, aged 18–70  years, with American Society of 
Anesthesiologists (ASA) physical status I or II undergoing neuraxial 
anaesthesia (spinal, or combined spinal and epidural anaesthesia) 
for elective orthopaedic, gynaecology or general surgery were 
enrolled in this study. The following groups of patients were 
excluded from the study: patients with a history of convulsions, 
hypo- or hyperthyroidism, cardiopulmonary disease, psychiatric 
disorders, neuromuscular pathology, an allergy to the study 
drugs, those with an initial heart rate < 50 beats/minute, systolic 
blood pressure  <  100  mmHg and body temperature  >  38.0  °C 
or  <  36.0  °C prior to anaesthesia. Shivering was graded with a 
scale similar to that validated by Crossley and Mahajan13 
(Appendix A). Only patients who developed grade 3 or 4 shivering 
were included in this study. Body temperature (tympanic 
membrane temperature) was measured with a Microlife Ear 
Digital Thermometer IR 1DE1-1® at the start of shivering and 5, 10 
and 15 minutes after commencement of treatment of shivering. 
The ambient temperature of the operating room was set at 
20 ± 1 °C, with a relative humidity of 60%. None of the patients 
were given premedication drugs. Standard monitoring was used 
throughout the operation.
Subarachnoid anaesthesia was instituted at the lumbar vertebra 
3–4 or 4–5 interspaces, with 15 mg hyperbaric bupivacaine. The 
volume of intravenous fluid and the use of ephedrine for 
hypotension, atropine for bradycardia and metoclopramide for 
nausea or vomiting were determined by the attending 
anaesthesiologist. The administration of pre- or intraoperative 
opioids was not permitted. Patients were supplemented with 
oxygen 5.0 l/minute by face mask, and covered with one layer of 
surgical drape and one layer of cotton blanket (over the non-
surgical field area), but not actively warmed during anaesthesia. 
The preloading fluids were preheated to 37 °C.
Of the 102 patients, the 60 who shivered (grade 3 or 4) during the 
operation under neuraxial anaesthesia were randomly allocated 
to receive either dexmedetomidine 0.5 μg/kg (n = 20), pethidine 
0.5 mg/kg (n = 20) or tramadol 0.5 mg/kg (n = 20), using computer-
generated randomised numbers. The study drugs were diluted to 
the same volume of 5.0  ml, and given intravenously over 3–5 
minutes.
Once the patients began shivering, the anaesthesiologist would 
administer the treatment drugs and measure the time that 
elapsed from commencement of the treatment to the cessation 
of shivering. If the shivering did not cease after 15 minutes, the 
treatment was regarded as ineffective. Treatment efficacy was 
evaluated subjectively by the patient as “no improvement”, 
“partial improvement” or “marked improvement”. Vital signs were 
measured before, and 5, 10 and 15 minutes after treatment. Side-
effects, such as pruritus, hypotension (a fall in systolic blood 
pressure > 20% from baseline), bradycardia (< 45 beats/minute), 
and nausea, vomiting and dizziness were recorded. The degree of 
sedation was recorded according to the Ramsay Sedation Score6 
(Appendix A).
Statistical analysis
A study population of 20 patients for each group was determined 
to have statistical power of 80% at an α-value of 0.05 to enable 
detection of a difference of 47% in the cessation of shivering 
within 15 minutes post treatment compared with the 
dexmedetomidine group, in response to pethidine and tramadol 
groups.
Statistical analysis was performed using Statistical Package for 
Social Sciences® software. Parametric data were analysed using 
one-way analysis of variance. Non-parametric data were analysed 
by using the chi-square test. A p-value of < 0.05 was considered to 
be statistically significant.
Results
In our study, 60 of the 102 patients (59%) experienced grade 3 or 
4 shivering. Those who shivered were randomly allocated to 
receive exmedetomidine, pethidine or tramadol. Table 1 shows 
that the three groups were comparable with respect to age, 
weight, height, gender, race, ASA status and type of surgery.
The responses of post-neuraxial anaesthesia shivering after 
treatment are shown in Table 2. The response rate was found to 
be highest in the dexmedetomidine group, and it was only 
significant when compared to the tramadol group (p = 0.0012). It 
was noted that although the response rate was higher in the 
pethidine group than in the tramadol group, the difference was 
not statistically significant (p  =  0.082). There was no significant 
difference in terms of the time that elapsed from the start of 
treatment to the cessation of shivering and patient-assessed 
treatment efficiency between the three groups.
It was noted in all three groups that core body temperature at 15 
minutes post treatment was lower than the core body temperature 
at the baseline, but the difference was not significant. Patients in 
the dexmedetomidine group had the lowest core body 
temperature at 15 minutes post treatment, but the difference 
between the three groups was not significant (Figure 1).
Figure 2 shows the Ramsay Sedation Score for all three groups 
post treatment. The difference in the sedation score in the three 
groups was statistically insignificant (p > 0.05).
In this analysis, hypotension and bradycardia were more common 
in the dexmedetomidine group during the 15-minutes study 
period, and the difference was significant when compared with 
the pethidine and tramadol groups. Only one patient in the 
tramadol group experienced nausea and vomiting (Table 3).
Discussion
The incidence of shivering during neuraxial anaesthesia was 59% 
in this study. This is comparable to that in studies conducted by 
Sagir et al. (55%)14 and Bilotta et al. (57%).15 Larry and Donal 
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mentioned in their article that in a broad sample of 21 studies, the 
median incidence of shivering in the control group was 55%.1
The efficacy of dexmedetomidine in treating and preventing 
shivering in various clinical scenarios has been demonstrated in 
previous studies.12 In our study, all patients treated with 
dexmedetomidine stopped shivering within 15 minutes post 
treatment. This result corresponds with that in the study 
conducted by Easley et al. which showed that 24 children ranging 
in age from 7–16 years old experienced the cessation of shivering 
behaviour within five minutes following the completion of 
dexmedetomidine administration.12 The difference between our 
study and their study was that ours involved adult patients who 
experienced shivering post neuraxial anaesthesia, while theirs 
involved children who shivered post general anaesthesia. The 
shivering that occurs during neuraxial anaesthesia and general 
anaesthesia share a common pathogenesis. Thus, agents that 
have proven successful in the treatment of shivering following 
neuraxial anaesthesia might also be useful in the management of 
shivering during general anaesthesia.1
Dexmedetomidine has been shown to reduce the core temperature 
and our results correlate with these findings.16 Studies in healthy 
volunteers have demonstrated that dexmedetomidine controls 
Table 1: Demographic, anaesthetic and surgical data*
Data Group
Dexmedetomidine (n = 20) Pethidine (n = 20) Tramadol (n = 20)
Age (years) 45.0 ± 14.3 47.7 ± 15.3 48.6 ± 13.2
Gender
Male 9 (45) 5 (20) 5 (25)
Female 11 (55) 16 (80) 15 (75)
Race
Malay 12 (60) 15 (75) 10 (50)
Chinese 6 (30) 4 (20) 8 (40)
Indian 1 (5) 1 (5) 1 (5)
Others 1 (5) 0 (0) 1 (5)
Weight (kg) 67.1 ± 13.4 60.5 ± 10.7 62.4 ± 13.5
Height (m) 158.3 ± 6.3 159.0 ± 9.1 157.2 ± 5.3
ASA status
I 10 (50) 5 (25) 6 (30)
II 10 (50) 15 (75) 14 (70)
Types of neuraxial anaesthesia
Subarachnoid or spinal 9 (45) 17 (85) 16 (80)
Combined spinal epidural 11 (55) 3 (15) 4 (20)
Types of surgery
Orthopaedic 12 (60) 7 (35) 6 (30)
General surgery 5 (25) 4 (20) 2 (10)
Gynaecological 3 (15) 9 (45) 12 (60)
Shivering grade
3 11 (55) 12 (60) 13 (65)
4 9 (45) 8 (40) 7 (35)
ASA: American Society of Anesthesiologists
*: Values expressed as mean ± standard deviation, number (n) and percentage in parenthesis
Table 2: Responses of post-neuraxial anaesthesia shivering after treatment*
Group
Dexmedetomidine (n = 20) Pethidine (n = 20) Tramadol (n = 20)
Response rate 20 (100)** 17 (85) 11 (55)**
Time elapsed from treatment to cessation of shivering (minutes) 7.3 ± 3.8  
(n = 11)
6.2 ± 2.3  
(n = 17)
5.9 ± 2.1  
(n = 20)
Patient-assessed treatment efficacy
No improvement 0 (0) 2 (10) 5 (25)
Partial improvement 0 (0) 1 (5) 4 (20)
Marked improvement 20 (100) 17 (85) 11 (55)
*: Values are expressed as mean ± standard deviation, number (n) and percentage in parenthesis
**: p < 0.05
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Figure 1: Mean tympanic temperature post treatment between the three groups
Figure 2: Ramsay Sedation Score post treatment between the three groups
Table 3: Observed side-effect*
Side-effects
Group
Dexmedetomidine (n = 20) Pethidine (n = 20) Tramadol (n = 20) p-value
Hypotension 5 (25) 0 (0) 2 (10) < 0.05
Bradycardia 4 (20) 0 (0) 0 (0) < 0.05
Nausea and vomiting 0 (0) 0 (0) 1 (5) > 0.05
*: Values are expressed in number and percentage in parenthesis
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Conclusion
In conclusion, dexmedetomidine 0.5  μg/kg was more effective 
than tramadol 0.5  mg/kg and pethidine 0.5  mg/kg, and both 
tramadol and pethidine were found to have similar efficacy, in the 
treatment of post-neuraxial anaesthesia shivering. However, 
dexmedetomidine caused a higher incidence of hypotension and 
bradycardia.
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shivering by reducing the shivering threshold.17−19 Doufas et al. 
carried out a study in which shivering was induced by infusing cold 
Ringer’s lactate solution (≈ 4 °C) into healthy adult volunteers. The 
results showed that the shivering threshold was 35.5–36.5 °C in the 
group treated with dexmedetomidine.17 However, in our study, 
patients did not shiver, even though their temperature was in the 
range of 35.8–35.9 °C. This might be owing to a difference in the 
mechanism of shivering under neuraxial anaesthesia compared to 
that induced by cold Ringer’s lactate solution.
Horn et al. showed that 0.5 mg/kg of pethidine was an effective 
dose for the treatment of shivering, which is why we administered 
pethidine 0.5  mg/kg to our patients with grade 3 shivering or 
higher.20 In 1999, Wang et al. showed that the response rate with 
pethidine (0.4  mg/kg) was 83% at five minutes and 93% at 30 
minutes.21 On the other hand, in the study by Bhatnagar et al., the 
response rate to pethidine (0.5  mg/kg) was only 80%.22 In our 
study, the response rate with pethidine was 85%, which is 
comparable with these two studies, although they were 
performed in post-general anaesthesia patients and not in post-
neuraxial anaesthesia patients. The disadvantages of pethidine 
treatment are the side-effects of nausea, vomiting, sedation and 
respiratory depression, but these did not occur in our patients 
with the dosage we used.
In the study by Chan et al., intravenous tramadol 0.25  mg/kg 
effectively controlled shivering (92%) during Caesarean delivery 
under neuraxial anaesthesia with minimal side-effects.8 Tsai and 
Chu conducted a study on parturients who shivered post epidural 
anaesthesia, and found that 87% who received tramadol (0.5 mg/
kg) stopped shivered within 15 minutes of treatment.4 In our study, 
55% patients stopped shivering within 15 minutes of receiving 
tramadol (0.5 mg/kg). The better response of patients to tramadol 
in the Tsai and Chu study may relate to the fact that their patients 
were pregnant women. The mechanism of shivering during 
epidural anaesthesia in parturients may be different from that in 
non-parturients. The disadvantages of tramadol are the side-
effects of nausea, vomiting and sedation. In our study, one patient 
developed nausea and vomiting, two developed hypotension and 
none were sedated post treatment with tramadol.
We have demonstrated that dexmedetomidine, pethidine and 
tramadol effectively treat post-neuraxial anaesthesia shivering. 
Dexmedetomidine appears to be more effective than pethidine 
and tramadol (100% vs. 85% vs. 55%, respectively). However, the 
only significant difference statistically was demonstrated 
between dexmedetomidine and tramadol (p  =  0.0012), not 
between dexmedetomidine and pethidine, or pethidine and 
tramadol, in reducing post-neuraxial anaesthesia shivering. Tsai 
and Chu showed that both tramadol (0.5 mg/kg) and pethidine 
(0.5  mg/kg) effectively treated post-epidural anaesthesia 
shivering.4 Seifi et al. noted that both tramadol (1.0 mg/kg) and 
pethidine (0.5  mg/kg) effectively reduced postoperative 
shivering, but there was no significant difference between them.23
Hypotension and bradycardia are known haemodynamic effects 
of dexmedetomidine.24−26 In our study, five patients developed 
hypotension and four developed bradycardia after receiving this 
drug. Nausea was also one of the adverse effects experienced, as 
shown in previous studies.26,27 But, in our study, none of the 
patients developed nausea or vomiting. All of the patients who 
received dexmedetomidine were cooperative, orientated, tranquil 
and could respond to commands, and these findings were similar 
to the results obtained in the study conducted by Elvan et al.6
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0 – No shivering
1 –  Piloerection or peripheral vasoconstriction, but no visible shivering
2 – Muscular activity in only one muscle group
3 –  Muscular activity in more than one muscle group, but not generalised
4 – Shivering involving the whole body.
Ramsay Sedation Score
1 – The patient is anxious and agitated, or restless, or both
2 – The patient is cooperative, oriented and tranquil
3 – The patient responds to commands only
4 –  The patient exhibits a brisk response to a light glabellar tap or to a loud auditory stimulus
5 –  The patient exhibits a sluggish response to a light glabellar tap or a loud auditory stimulus
6 – The patient exhibits no response.
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